New eczema drug enters early human safety testing
NCT ID NCT07549984
First seen Apr 29, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called IBI3033 in 16 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and tolerable, not to cure the disease. Participants will receive either the drug or a placebo over 12 weeks, with follow-up for 4 more weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hangzhou First People's Hospital
Hangzhou, Hangzhou, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.